BOSTON, Aug. 14, 2019 /PRNewswire/ -- Wanted:
high-potential life sciences and biotech start-up companies looking
for an opportunity to be part of a vibrant innovation ecosystem
where companies develop truly transformational science.
Novo Nordisk, a global healthcare company committed to
discovering, creating and co-creating innovation to solve
healthcare challenges for people living with diabetes and other
serious chronic diseases, issues an open call for promising
start-up companies to submit non-confidential proposals for a Novo
Nordisk-sponsored LabCentral "Golden Ticket." The winner will have
the chance to receive access for one scientist and one bench at
LabCentral's state-of-the-art shared lab space in Boston for research for one year. Novo Nordisk
will award one Golden Ticket a year for three years.
Proposals should focus on solutions supporting therapeutic areas
that align with Novo Nordisk's focus areas: diabetes (type 1, type
2, and resulting complications), obesity, cardiovascular disease,
NASH, chronic kidney disease, hemophilia, or technologies that can
be applied to these diseases such as new therapeutic platforms,
cell therapies (stem cell) or differentiation protocols, cell
encapsulation technologies, novel platforms for RNA-based
therapies, novel platforms for gene-editing, formulation and drug
delivery technologies, exosomes, and other cell penetrating
technologies.
Life sciences start-ups interested in winning the LabCentral
space should review the full competition terms and conditions to
submit their "Golden Ticket" application. Companies that meet the
eligibility requirements must apply by Friday, September 20, 2019.
A select number of companies will be invited to present their
proposals to Novo Nordisk in the fall of 2019. The winner will be
announced at a ceremony for the Boston Biotech and Academic
community.
LabCentral, just a short walk from Novo Nordisk's new Boston
Innovation Hub in Kendall Square, is a first-of-its-kind shared
laboratory space located in the heart of Cambridge, Mass. It is designed as a launchpad
for high-potential life sciences and biotech start-ups.
Novo Nordisk has a long-standing scientific leadership in
therapeutic and device innovation and recently established the Novo
Nordisk Boston Innovation Hub to expand its US-based collaborations
and partnerships.
"One of the reason's we're in Boston is to be a part of this thriving and
vibrant life sciences ecosystem," said John
McDonald, corporate vice president and head of the Novo
Nordisk Boston Innovation Hub. "Along with our academic
collaborations in Boston, working
with LabCentral is another way we're looking to help foster
innovation that can ultimately help people with chronic disease
live healthier lives. This is just the beginning of Novo Nordisk's
contribution to Boston's
scientific community."
Novo Nordisk A/S, a global healthcare company, organized this
"Golden Ticket" competition.
About Novo Nordisk in the US
Novo Nordisk, a global
healthcare company, has been committed to discovering and
developing innovative medicines to help people living with diabetes
lead longer, healthier lives for 95 years. This heritage has given
us experience and capabilities that also enable us to help people
defeat other serious diseases including obesity, hemophilia and
growth disorders. We remain steadfast in our conviction that the
formula for success is to stay focused, think long term and do
business in a financially, socially and environmentally responsible
way. With U.S. headquarters in New Jersey and production
and research facilities in six states, Novo Nordisk employs nearly
6,000 people throughout the country. For more information,
visit novonordisk.us, Facebook, Instagram and Twitter.
About LabCentral
LabCentral provides fully equipped,
permitted, and supported lab space for biomedical research, plus
programming and unmatched networking opportunities to help
start-ups advance their science and build their companies. It
provides first-class facility and administrative support, skilled
laboratory personnel, a domain-relevant expert speaker series – as
well as the other critical services and support that start-ups need
to begin laboratory operations on day one. A private, non-profit
institution, LabCentral was funded in part by a $5 million grant from the Massachusetts Life
Sciences Center, with support from its real estate partner,
MIT.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/calling-life-science-innovators-dont-miss-your-chance-for-a-golden-ticket-to-labcentral-300901793.html
SOURCE Novo Nordisk